Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Failure of metabolic checkpoint control during late-stage granulopoiesis drives neutropenia in reticular dysgenesis

Wenqing Wang, Martin Arreola, Thomas Mathews, Andrew W DeVilbiss, Zhiyu Zhao, Misty Martin-Sandoval, Abdulvasey Mohammed, Giorgia Benegiamo, Avni Awani, Ludger J. E. Goeminne, Daniel Patrick Dever, Yusuke Nakauchi, Matthew H Porteus, Mara Pavel-Dinu, Waleed Al Herz, Johan Auwerx, Sean J. Morrison, Katja G. Weinacht

Blood blood.2024024123.

https://doi.org/10.1182/blood.2024024123

Published: 2024

Includes: Supplemental data

Journal Articles

Intra-Leukemic IFNγ Signaling Mediates Cell Cycle Suppression and Chemoresistance in AML

Daiki Karigane, Amy C Fan, Kensuke Kayamori, Yusuke Nakauchi, Thomas Koehnke, Athreya S Rangavajhula, Asiri Ediriwickrema, Ravindra Majeti

Blood (2023) 142 (Supplement 1): 406.

https://doi.org/10.1182/blood-2023-181430

Published: 2023

Journal Articles

Engineering Sequential Mutations into Human HSPCs Yields an Aggressive Myeloid Malignancy Allowing for Interrogation of Preleukemic Transformation

Cailin T Collins, Yusuke Nakauchi, Thomas Koehnke, James S Chavez, Suyoun Choi, Rajiv Sharma, Feifei Zhao, Ravindra Majeti

Blood (2023) 142 (Supplement 1): 953.

https://doi.org/10.1182/blood-2023-187422

Published: 2023

Journal Articles

BCOR Loss Confers Increased Stemness and Partially Rescues RUNX1-Deficient Phenotypes in Human Hematopoietic Stem and Progenitor Cells

Kendra K Jackson, Amy C Fan, Daiki Karigane, Feifei Zhao, Cailin T Collins, Yusuke Nakauchi, Kensuke Kayamori, Athreya S Rangavajhula, Thomas Koehnke, Ravindra Majeti

Blood (2023) 142 (Supplement 1): 946.

https://doi.org/10.1182/blood-2023-187865

Published: 2023

Journal Articles

Gene Correction of DNMT3A:R882H in Primary Human AML Demonstrates That This Mutation Is Not Required for Disease Maintenance, but Is Associated with Increased Leukemia Stem Cell Frequency

Thomas Koehnke, Daiki Karigane, Eleanor Hilgart, Kensuke Kayamori, Amy C Fan, Cailin T Collins, Fabian P Suchy, Athreya S Rangavajhula, Yang Feng, Yusuke Nakauchi, Eduardo Martinez-Montes, Michael Koldobskiy, Andy Feinberg, Ravindra Majeti

Blood (2023) 142 (Supplement 1): 579.

https://doi.org/10.1182/blood-2023-186440

Published: 2023

Journal Articles

Targeting IDH1-Mutated Pre-Leukemic Hematopoietic Stem Cells in Myeloid Disease, Including CCUS and AML

Niklas Landberg, Thomas Koehnke, Yusuke Nakauchi, Amy Fan, Daiki Karigane, Daniel Thomas, Ravindra Majeti

Blood (2022) 140 (Supplement 1): 2234–2235.

https://doi.org/10.1182/blood-2022-159617

Published: 2022

Journal Articles

Cytokine Rescue and Targeting of Inflammation-Sensitive RUNX1 Deficient Human CD34 + Hematopoietic Stem and Progenitor Cells

Amy Fan, Armon Azizi, BS, Kevin Nuno, BS, Yusuke Nakauchi, MD PhD, Feifei Zhao, MD, Andreas Reinisch, MD PhD, David Cruz Hernandez, MS, Ravindra Majeti, MD PhD

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-137173

Published: 2020

Journal Articles

Enasidenib Drives Maturation of Human Erythroid Precursors Independently of IDH2

Ritika Dutta, BS, Tian Y Zhang, MD PhD, Thomas Koehnke, MD, Daniel Thomas, MD PhD, Eric Gars, MD, Melissa Stafford, Yusuke Nakauchi, MD PhD, Satinder Kaur, BS, Raymond Yin, Anupama Narla, MD, Ravindra Majeti, MD PhD

Blood (2019) 134 (Supplement_1): 540.

https://doi.org/10.1182/blood-2019-124551

Published: 2019

Journal Articles

Induction of Truncating ASXL1 Mutations in Human CD34+ HSPCs Mimics Human ASXL1-Mutated Clonal Hematopoiesis and Progression to Myeloid Malignancies

Thomas Koehnke, MD, Rajiv Sharma, PhD, Yusuke Nakauchi, MD PhD, Andreas Reinisch, MD PhD, Ravi Majeti, MD PhD

Blood (2019) 134 (Supplement_1): 820.

https://doi.org/10.1182/blood-2019-130528

Published: 2019

Journal Articles

An Engineered Cell-Traceable Model of Reticular Dysgenesis in Human Hematopoietic Stem Cells Linking Metabolism and Differentiation

Wenqing Wang, PhD, Avni Awani, PhD, Lauren Reich, Yusuke Nakauchi, MD PhD, Daniel Thomas, MD PhD, Daniel P. Dever, PhD, Matthew Porteus, MD PhD, Katja G. Weinacht, MD PhD

Blood (2018) 132 (Supplement 1): 2558.

https://doi.org/10.1182/blood-2018-99-117926

Published: 2018

Journal Articles

Azacitidine and Ascorbate Inhibit the Competitive Outgrowth of Human TET2 Mutant HSPCs in a Xenograft Model of Pre-Leukemia

Yusuke Nakauchi, MD PhD, Daniel Thomas, MD PhD, Rajiv Sharma, PhD, M. Ryan Corces, PhD, Andreas Reinisch, MD PhD, David Cruz, MS, Thomas Koehnke, MD PhD, Daiki Karigane, MDPhD, Amy Fan, BS, Ravindra Majeti, MD PhD

Blood (2018) 132 (Supplement 1): 887.

https://doi.org/10.1182/blood-2018-99-113907

Published: 2018

Journal Articles

IDH1 Mutant AML Is Susceptible to Targeting De Novo Lipid Synthesis Independent of 2-Hydroxyglutarate and Has a Distinct Metabolic Profile from IDH2 Mutant AML

Daniel Thomas, MD PhD, Yusuke Nakauchi, MD PhD, Manhong Wu, PhD, Ming Zheng, PhD, Subarna Sinha, PhD, David Dill, PhD, Gary Peltz, MD PhD, Ravindra Majeti, MD PhD

Blood (2018) 132 (Supplement 1): 440.

https://doi.org/10.1182/blood-2018-99-115040

Published: 2018

Journal Articles

Characterization and Targeting TET2-Mutant HSPCs and AML

Yusuke Nakauchi, MD PhD, Daniel Thomas, MD PhD, Andreas Reinisch, MD PhD, Rajiv Sharma, PhD, David Cruz, BS, M. Ryan Corces, PhD, Ravi Majeti, MD PhD

Blood (2017) 130 (Supplement 1): 2509.

https://doi.org/10.1182/blood.V130.Suppl_1.2509.2509

Published: 2017

Journal Articles

Establishment of a Therapeutic Anti-Pan HLA-Class II Monoclonal Antibody That Directly Induces Lymphoma Cell Death Via Large Pore Formation

Shuji Matsuoka, MDPhD, Yasuyuki Ishii, PhD, Atsuhito Nakao, MDPhD, Hiroshi Masutani, Satoshi Takahashi, MD PhD, Yusuke Nakauchi, MD, Okio Hino, MDPhD

Blood (2014) 124 (21): 5488.

https://doi.org/10.1182/blood.V124.21.5488.5488

Published: 2014

Journal Articles

Novel Therapeutic Approach To Graft-Versus-Host Disease With Allele-Specific Anti-HLA Monoclonal Antibody

Yusuke Nakauchi, MD, Satoshi Yamazaki, PhD, Stephanie Carlisle Napier, Jo-ichi Usui, MD, PhD, Yasunori Ota, MD, PhD, Satoshi Takahashi, MD, PhD, Nobukazu Watanabe, MD, PhD, Hiromitsu Nakauchi, MD, PhD

Blood (2013) 122 (21): 4462.

https://doi.org/10.1182/blood.V122.21.4462.4462

Published: 2013

Journal Articles

Development of Antigen Specific T Cells After HLA-Mismatched Umbilical Cord Blood Transplantation

Yusuke Nakauchi, M.D., Dayong Zhu, M.D., Ph.D., Satoshi Takahashi, M.D., Ph.D., Aikichi Iwamoto, M.D., Ph.D., Hiromitsu Nakauchi, MD, PhD, Nobukazu Watanabe, M.D., Ph.D.

Blood (2011) 118 (21): 4544.

https://doi.org/10.1182/blood.V118.21.4544.4544

Published: 2011

NARROW

Failure of metabolic checkpoint control during late-stage granulopoiesis drives neutropenia in reticular dysgenesis

Intra-Leukemic IFNγ Signaling Mediates Cell Cycle Suppression and Chemoresistance in AML

Engineering Sequential Mutations into Human HSPCs Yields an Aggressive Myeloid Malignancy Allowing for Interrogation of Preleukemic Transformation

BCOR Loss Confers Increased Stemness and Partially Rescues RUNX1-Deficient Phenotypes in Human Hematopoietic Stem and Progenitor Cells

Gene Correction of DNMT3A:R882H in Primary Human AML Demonstrates That This Mutation Is Not Required for Disease Maintenance, but Is Associated with Increased Leukemia Stem Cell Frequency

Targeting IDH1-Mutated Pre-Leukemic Hematopoietic Stem Cells in Myeloid Disease, Including CCUS and AML

Cytokine Rescue and Targeting of Inflammation-Sensitive RUNX1 Deficient Human CD34 + Hematopoietic Stem and Progenitor Cells

Enasidenib Drives Maturation of Human Erythroid Precursors Independently of IDH2

Induction of Truncating ASXL1 Mutations in Human CD34+ HSPCs Mimics Human ASXL1-Mutated Clonal Hematopoiesis and Progression to Myeloid Malignancies

An Engineered Cell-Traceable Model of Reticular Dysgenesis in Human Hematopoietic Stem Cells Linking Metabolism and Differentiation

Azacitidine and Ascorbate Inhibit the Competitive Outgrowth of Human TET2 Mutant HSPCs in a Xenograft Model of Pre-Leukemia

IDH1 Mutant AML Is Susceptible to Targeting De Novo Lipid Synthesis Independent of 2-Hydroxyglutarate and Has a Distinct Metabolic Profile from IDH2 Mutant AML

Characterization and Targeting TET2-Mutant HSPCs and AML

Establishment of a Therapeutic Anti-Pan HLA-Class II Monoclonal Antibody That Directly Induces Lymphoma Cell Death Via Large Pore Formation

Novel Therapeutic Approach To Graft-Versus-Host Disease With Allele-Specific Anti-HLA Monoclonal Antibody

Development of Antigen Specific T Cells After HLA-Mismatched Umbilical Cord Blood Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only